News Johnson & Johnson’s Rybrevant Plus Lazcluze Receives the CHMP’s Positive Opinion as a 1L Treatment of EGFR-Mutated NSCLCByDipanshu DixitNovember 15, 20240Comments
News InflaRx’s Gohibic (Vilobelimab) Gains the CHMP’s Positive Opinion for the Treatment of ARDS ByDipanshu DixitNovember 15, 20240Comments
News BMS’ Augtyro (Repotrectinib) Gains the CHMP’s Positive Opinion to Treat Advanced ROS1+ NSCLC and NTRK+ Solid Tumors ByDipanshu DixitNovember 15, 20240Comments
TOP 20 20 Contract Development and Manufacturing Organizations (CDMO) of 2024ByPrince GiriNovember 14, 20240Comments
THOUGHTSPOT Bridging the Biopharma Gap with Consulting FirmsBySaurabh ChaubeyNovember 13, 20240Comments
THOUGHTSPOT Balanced Health: How Holistic Practices and Supplements Work Together for WellnessByAndrea LaceyNovember 13, 20240Comments
SPOTLIGHT CXO Talks: Jed Litwiniuk & Uwe Tigör from Auxilius Pharma in a Riveting Dialogue Exchange with PharmaShotsByHimanshu SehgalNovember 11, 20240Comments
